Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9974265 | 0.85 | SIGMAR1 (0.65) | SIGMAR1KCNH2 | |
| SCHEMBL8234160 | 0.83 | SIGMAR1 (0.71) | SIGMAR1KCNH2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9974264 | 0.83 | SIGMAR1 (0.77) | SIGMAR1KCNH2 | |
| SCHEMBL4560695 | 0.79 | SIGMAR1 (0.52) | SIGMAR1KCNH2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1980077 | 0.71 | SIGMAR1 (0.60) | SIGMAR1 | |
| SCHEMBL4521954 | 0.68 | SIGMAR1 (0.80) | SIGMAR1KCNH2 | |
| SCHEMBL7927032 | 0.66 | NOTUM (0.40) | SIGMAR1KCNH2LMNA | |
| Oxalic Acid SCHEMBL4508376 | 0.66 | SIGMAR1 (0.75) | SIGMAR1KCNH2 | |
| SCHEMBL4500443 | 0.66 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL12187054 | 0.66 | SIGMAR1 (0.76) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202872-B2 | Pyrazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-19 | — | — | US | disclosed |
| US-20090264442-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVES, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264442-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885KCNH2 1469/4885CYP1A2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.